Creo Medical ( (GB:CREO) ) just unveiled an announcement.
Creo Medical Group plc has announced investor presentations scheduled for May 19, 2025, following the release of their preliminary results for the year ending December 31, 2024. The presentations, led by key executives, will outline the company’s commercial strategy and efforts towards achieving commercial profitability. These events, available both online and in-person, aim to engage existing and potential shareholders by providing insights into Creo’s financial performance and future growth plans.
More about Creo Medical
Creo Medical Group plc is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices. Their focus is on enhancing patient outcomes through advanced energy solutions in endoscopy, utilizing their proprietary CROMA technology powered by Kamaptive. This technology integrates multi-modal energy sources to improve surgical precision and flexibility, offering safer and more cost-efficient options for surgical and endoscopic procedures.
YTD Price Performance: -45.51%
Average Trading Volume: 1,332,049
Technical Sentiment Signal: Buy
Current Market Cap: £43.83M
Learn more about CREO stock on TipRanks’ Stock Analysis page.